CLONAPAM Comprimé
Country: Canada
Language: French
Source: Health Canada
Summary of Product characteristics
(SPC)
08-03-2021
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
Clonazépam
Available from:
BAUSCH HEALTH, CANADA INC.
ATC code:
N03AE01
INN (International Name):
CLONAZEPAM
Dosage:
2MG
Pharmaceutical form:
Comprimé
Composition:
Clonazépam 2MG
Administration route:
Orale
Units in package:
100/500
Prescription type:
Ciblés (LRCDAS IV)
Therapeutic area:
BENZODIAZEPINES
Product summary:
Numéro de groupe d'ingrédients actifs (GIA) :0111558002; AHFS:
Authorization status:
APPROUVÉ
Authorization date:
2021-03-10
Summary of Product characteristics
MONOGRAPHIE DE PRODUIT
T/C
CLONAPAM
MD
Comprimésdeclonazépam, USP
Comprimés à 0,5mg,1 mg età2 mg
Anticonvulsivant
BauschHealth, CanadaInc.
2150St-Elzear Blvd.Ouest
Laval,Québec
H7L 4A8
Numérodecontrôle #: 248606
Datede révision:
8mars2021
T/C
CLONAPAM
MD
Monographiedeproduit
Page2 de 32
Tabledes matières
PARTIE I:RENSEIGNEMENTS POUR LE PROFESSIONNEL DE LASANTÉ
.................... 3
RENSEIGNEMENTS SOMMAIRES SURLEPRODUIT
...................................................... 3
INDICATIONSETUSAGECLINIQUE
..................................................................................
3
CONTRE-INDICATIONS.........................................................................................................
4
MISESENGARDEETPRÉCAUTIONS.................................................................................
4
RÉACTIONS INDÉSIRABLES
..............................................................................................
10
INTERACTIONSMÉDICAMENTEUSES
............................................................................
12
POSOLOGIEET ADMINISTRATION
..................................................................................
14
SURDOSAGE
..........................................................................................................................
15
MODE D’ACTIONET PHARMACOLOGIECLINIQUE
.................................................... 17
STABILITÉ ETENTREPOSAGE
..........................................................................................
18
INSTRUCTIONSSPÉCIALES DEMANUTENTION
.......................................................... 19
PRÉSENTATION,COMPOSITIONETCONDITIONNEMENT
......................................... 19
PARTIE II : RENSEIGNEMENTS SCIENTIFIQUES
................................................................. 20
RENSEIGNEMENTS PHARMACEUTIQUES
......................................................................
20
ESSAISCLINIQUES
..............................................................................................
Read the complete document
